Chairman of Cystic Fibrosis Center Utrecht

Chairman of Dutch Cystic Fibrosis Research Network

Member of Medical Advisory Board Dutch Cystic Fibrosis Committee

Member of Research committee Wilhelmina Children’s Hospital Utrecht

Member of Medical Ethical Committee University Medical Center Utrecht

Medical advisor of Sioux CCM

Board Member of Malawi Mission Work Team

Chair of CoreNetwork CF of European Refence Network of Excellence for rare lung diseases (ERN-LUNG) 2015-now

Member steering committee Clinical Trial Office UMC Utrecht 2017-now

Coordinator of European HIT-CF program 2018-now

Board member of Lung Alliance Netherlands (LAN) 2020-now

Reviewer for Am J Resp Crit Care Med, European Respir J and many others

Reviewer for the expertise centra voor zeldzame ziekte voor de NFU 2021 - heden

Chair of therapeutic foundation 2021 - heden

Potential Conflicts of Interest

Dr. van der Ent reports grants from GSK, grants from Nutricia, grants from TEVA, grants from Gilead, grants from Vertex, grants from ProQR, grants from Proteostasis, grants from Galapagos NV, grants from Eloxx and grants from Santhera, all paid to UMCU; In addition, Dr. van der Ent has a patent 10006904 with royalties paid.

https://www.linkedin.com/profile/view?id=173991063&authType=NAME_SEARCH&authToken=I-yR&locale=nl_NL&trk=tyah2&trkInfo=idx%3A1-1-1%2CtarId%3A1426146211550%2Ctas%3Akors+va

https://www.youtube.com/watch?v=hnOh3tOkI7Y

The research interests of professor Kors van der Ent focus on the themes Cystic Fibrosis and other bronchusobstructive diseseases in young children. He is the leader of the national HIT-CF program which focuses on the development and personalised application of new drugs influencing the basis genetic defect in patients with CF. This program includes both mechanistic studies in collaboration with the Hubrecht lab and the Byvoet Center as well as studies into host pathogen interaction in collaboration with the veterinary faculty of the Utrecht University. Clinical studies are performed in close collaboration with other CF-centres throughout Europe. Furthermore, he was the founder of the Whistler birth cohort, in which thousands of children are followed from birth to study determinants of the development of respiratory diseases. These cohorts mirror normal development to understand mechanisms in disease.

Kors van der Ent has special interest in innovation and valorisation in medical care and believes in creation of hospital networks to build the future medical care system for children. He successfully developed new devices to measure neonatal lung function, which were launched to the market. He also developed the Luchtwegportaal, an interactive web-based system to collect patient data regarding respiratory diseases in many hospitals in The Netherlands.

European CF young investigator meeting award 2011. A functional CFTR assay using primary cystic fibrosis organoids

European CF basic science meeting award 2011. Treatment with VX809 and VX770 in rectal CF organoids expressing  uncommon CFTR genotypes

European CF basic science meeting award 2012. Characterizing altered inflammatory signaling in CFTR-defective

bronchial epithelial cells

National symposium Dutch CF foundation award 2011. Complement mediated phagocytosis is reduced in CF monocytes.